These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23355059)

  • 1. The reversal of inhibitors in congenital hemophilia.
    DeFrates SR; McDonagh KT; Adams VR
    Pharmacotherapy; 2013 Feb; 33(2):157-64. PubMed ID: 23355059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor eradication with rituximab in haemophilia: where do we stand?
    Franchini M; Mannucci PM
    Br J Haematol; 2014 Jun; 165(5):600-8. PubMed ID: 24628543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports.
    Streif W; Escuriola Ettingshausen C; Linde R; Kropshofer G; Zimmerhackl LB; Kreuz W
    Hamostaseologie; 2009 May; 29(2):151-4. PubMed ID: 19404522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA; Neufeld EJ; Bennett CM
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation factors with improved properties for hemophilia gene therapy.
    Pipe SW
    Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.
    Kruse-Jarres R
    Hematology Am Soc Hematol Educ Program; 2011; 2011():407-12. PubMed ID: 22160066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
    Benson G; Auerswald G; Elezović I; Lambert T; Ljung R; Morfini M; Remor E; Salek SZ
    Eur J Haematol; 2012 May; 88(5):371-9. PubMed ID: 22260405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor economics.
    Teitel J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S14-7. PubMed ID: 16690371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.